AIM
CORT icon

Anchor Investment Management’s Corcept Therapeutics CORT Stock Holding History

Anchor Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-350
Closed -$7.88K – 980
2022
Q1 		$7.88K Buy
+350
New +$7.45K ﹤0.01% 785

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Anchor Investment Management's CORT Position: Q2 2022 in Review

Anchor Investment Management sold out of Corcept Therapeutics (CORT) in Q2 2022, closing a stake of 350 shares — an estimated $7.88K sold.

Anchor Investment Management first reported a position in CORT in Q1 2022 and held it in 1 quarter. The position peaked at $7.88K in Q1 2022. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2022.

  • Anchor Investment Management reported no remaining Corcept Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Anchor Investment Management sold 350 Corcept Therapeutics shares in Q2 2022, an estimated $7.88K.
  • Anchor Investment Management first reported a position in Corcept Therapeutics in Q1 2022 and held it in 1 quarter.
  • Anchor Investment Management's Corcept Therapeutics position peaked at $7.88K in Q1 2022.
  • 225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2022.

Based on Anchor Investment Management's 13F filing for Q2 2022, filed 2 Jan 2024.